Fontan-Associated and Other Vascular Liver Diseases: Hepatocellular Carcinoma Risk, Surveillance, and Diagnosis
World Class Speakers
Description
HCC and other liver nodules can develop in patients with Fontan-associated liver disease (FALD) and other vascular liver diseases, which may include conditions such as heart failure and Budd-Chiari syndrome. Currently, the Liver Imaging Reporting and Data System (LI-RADS)—a widely used tool for the imaging diagnosis of HCC—cannot be applied to these patients due to insufficient data and the low specificity of imaging in this context. This session provides an overview of cardiac/vascular liver disease and associated HCC risk. Speakers discuss the controversial topic of HCC surveillance in patients without cirrhosis, explore appropriate surveillance strategies for high-risk patients including those with cirrhosis, and address the diagnostic challenges faced by this population.
Journey Maps
Presentations
Fontan-Associated and Cardiac Liver Disease and Hepatocellular Carcinoma Risk
Non-Fontan Vascular Liver Disease and Hepatocellular Carcinoma Risk
Hepatocellular Carcinoma: Surveillance Modalities and Patient Populations for Whom Surveillance Is Indicated
Diagnostic Challenges in Vascular Liver Disease: Modalities and When to Biopsy
Objectives
- Review cardiac liver disease including Fontan-associated liver disease (FALD) and other vascular liver diseases and HCC risk in this population.
- Discuss the challenges in HCC surveillance in cardiac and vascular liver disease, including how to risk stratify high-risk patients for HCC surveillance and the selection of optimal surveillance tests.
- Describe how to diagnose benign liver nodules and HCC in cardiac and vascular liver diseases.